Inhibitory Antibodies

Gemtuzumab Ozogamicin ist ein Antikörper-Wirkstoff-Konjugat (ADC), das aus einem monoklonalen Antikörper besteht, der auf CD33 abzielt und mit einem zytotoxischen Derivat von Calicheamicin verknüpft ist. Gemtuzumab Ozogamicin kann für die Erforschung von akuter myeloischer Leukämie verwendet werden.

Landogrozumab (LY2495655) is a humanized monoclonal antibody against myostatin. Landogrozumab can effectively improve muscle volume, grip strength and function. Landogrozumab can be used for research related to muscle atrophy diseases.

Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds with high affinity to the extracellular domain of human TIGIT (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used for cancer research.

Ontuxizumab (MORAb-004) is a monoclonal antibody of IgG1/κ against endosialin (TEM-1 or CD248), which has anti-tumor effects. Ontuxizumab can be used for cancer research.

Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1, with potential applications in acute optic neuritis and relapsing multiple sclerosis.

Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody that blocks FcRn. Orilanolimab inhibits the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impairs adaptive immune function mediated by FcRn activation of IgG ICs. Orilanolimab can disrupt IgG homeostasis and innate and adaptive immunity.

Pascolizumab (SB-240683) is a humanized monoclonal antibody against IL-4. Pascolizumab has the potential for asthma research.

Pepinemab (VX 15/2503) ist ein humanisierter monoklonaler Antikörper gegen SEMA4D. Signalprotein 4D (SEMA4D), auch bekannt als CD100, reguliert den Prozess der neuronalen Entwicklung und spielt eine Rolle in verschiedenen zellulären Prozessen. Pepinemab kann durch Blockieren der Aktivität von SEMA4D bei der Erforschung verschiedener neurodegenerativer Erkrankungen wie Alzheimer eingesetzt werden.

Prezalumab (AMG 557) is a human IgG2 monoclonal antibody that targets ICOSL and BAFF. Prezalumab has been studied for its effects on systemic lupus erythematosus arthritis. Prezalumab can be used in the research of skin lupus erythematosus, psoriasis, and systemic lupus erythematosus (SLE).

Rocatinlimab (AMG 451) (KHK4083) is a fully human, non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody against OX40. Rocatinlimab can be used for the study of atopic dermatitis (AD).

Rosmantuzumab (OMP-131R10) is a humanized monoclonal antibody against R-spondin 3 (RSPO3). Rosmantuzumab can be used for the study of advanced recurrent and refractory solid tumors.

Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its connection with the CD200 receptor (CD200R). Samalizumab can be used in research for multiple myeloma and B-cell chronic lymphocytic leukemia.

Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody. Sibeprenlimab can inhibit APRIL. Sibeprenlimab can be used for the study of IgA nephropathy (IgAN).

Sofituzumab (MMUC 1206A) is a human anti-MUC16 recombinant V-kappa antibody.

Sontuzumab (AS1402) is a humanized IgG1κ monoclonal antibody specific for MUC1. Sontuzumab binds to the extracellular MUC1 peptide sequence PDTR, with a Kd of approximately 1 nM. Sontuzumab can be used in breast cancer research.

Tanezumab (RN-624) is a humanized monoclonal antibody with high affinity and specificity that can block the binding of NGF to receptors p75 and TrkA in the peripheral nervous system. Tanezumab can be used for acute and chronic pain, such as osteoarthritis, knee joint and neuropathic pain, and postherpetic neuralgia research.

Tavolixizumab (MEDI 0562; Tavolimab) is a humanized monoclonal antibody against TNFRSF4 (TNF receptor superfamily member 4), which can be used in cancer immunology research.

Telazorlimab (GBR-830) is a humanized monoclonal antibody targeting the OX40 co-stimulatory receptor on activated T cells. Telazorlimab can be used for research in autoimmune diseases.

Telisotuzumab (ABT-700) is a humanized recombinant bivalent antibody that targets the hepatocyte growth factor receptor (MET) as a therapeutic antibody. It can bind to c-Met with high affinity and inhibit c-Met signaling. Telisotuzumab has anti-tumor activity.

Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks the proliferation of B lymphocytes. Telitacicept can be used in research on B cell autoimmune diseases.

Tenatumomab (ST2146) is a mouse-derived monoclonal antibody against tenascin-C, a large extracellular glycoprotein that is overexpressed in cancer. Tenatumomab has been used in pre-targeted radioimmunotherapy studies (PAGRIT) and delivers radioactive isotopes to tumors through PAGRIT and direct 131 iodine labeling methods.

Tesnatilimab is a humanized IgG4 monoclonal antibody that targets the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in research on inflammatory bowel disease (IBD).

Tregalizumab ist ein humanisierter monoklonaler Antikörper (IgG1-Typ), der selektiv die hemmenden Eigenschaften regulatorischer T-Zellen (Tregs) in vitro aktivieren kann. Tregalizumab wird zur Erforschung von Autoimmunerkrankungen (die aufgrund einer unzureichenden Aktivität von Tregs auftreten können) und Allergien eingesetzt.

TSR-033 ist ein hochaffines humanisiertes IgG4-Antikörper, das sich gegen LAG-3 (Lymphozytenaktivierungsgen-3) richtet und die Funktion von T-Zellen in vitro und in vivo sowie die PD-1-Blockade verstärken kann. LAG-3 ist ein ko-inhibitorischer Rezeptor, der mit der Funktionsstörung von T-Zellen assoziiert ist und oft gemeinsam mit PD-1 exprimiert wird. TSR-033 hat antitumorale Aktivität.

Vibostolimab is a monoclonal antibody against anti-TIGIT (T cell immunoglobulin and ITIM domain). Vibostolimab has shown anti-tumor activity and can be used for research on non-small cell lung cancer (NSCLC) and melanoma.

Vonlerolizumab (MOXR 0916) is a humanized IgG agonistic monoclonal antibody specific for OX40. Vonlerolizumab can be used in cancer research.

Vopratelimab (JTX-2011) is a humanized monoclonal antibody that acts as an immunoglobulin G1-kappa agonist, specifically binding to the inducible T cell co-stimulator (ICOS). Vopratelimab retains species cross-reactivity, with an affinity of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS. Vopratelimab has anti-tumor immune response properties.